4WEB, Inc. v. NuVasive, Inc.

CourtDistrict Court, S.D. California
DecidedSeptember 24, 2024
Docket3:24-cv-01021
StatusUnknown

This text of 4WEB, Inc. v. NuVasive, Inc. (4WEB, Inc. v. NuVasive, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
4WEB, Inc. v. NuVasive, Inc., (S.D. Cal. 2024).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 4WEB, INC., Case No.: 24-CV-1021 JLS (MMP)

12 Plaintiff, ORDER GRANTING IN PART AND 13 v. DENYING IN PART DEFENDANT’S MOTION FOR PATENT CLAIM 14 NUVASIVE, INC., REDUCTION 15 Defendant. (ECF No. 79) 16 17 18 19 20 Presently before the Court is Defendant NuVasive, Inc.’s Motion for Patent Claim 21 Reduction (“Mot,” ECF No. 79), to which Plaintiff 4WEB, Inc. filed an Opposition to 22 Defendant’s Motion for Patent Claim Reduction (“Opp’n,” ECF No. 84) and Defendant 23 filed a Reply (“Reply,” ECF No. 86). After considering the Parties’ arguments and the 24 law, the Court rules as follows. 25 BACKGROUND 26 Plaintiff accuses Defendant of infringing 128 claims across eleven patents relating 27 to spinal implant technology. The patents at issue are U.S. Patent Nos. 8,430,930 (the 28 “’930 patent”); 9,999,516 (the “’516 patent”); 9,545,317 (the “’317 patent”); 11,278,421 1 (the “’421 patent”); 9,271,845 (the “’845 patent”); 9,549,823 (the “’823 patent”); 2 9,572,669 (the “’669 patent”); 9,757,235 (the “’235 patent”); 10,849,756 (the “’756 3 patent”); 9,987,137 (the “’137 patent”); and 9,636,226 (the “’226 patent”). See ECF No. 21 4 (“FAC”) ¶¶ 71, 82, 92, 102, 112, 123, 134, 145, 156, 167, 178. 5 Defendant argues that the time is ripe for the Court to reduce the number of claims 6 because of the “unduly burdensome” nature of preparing detailed non-infringement and 7 invalidity arguments for all 128 asserted claims, Mot. at 4,1 many of which are duplicative, 8 id. at 6. Plaintiff counters that reducing the number of claims is premature because it has 9 not yet been privy to “significant fact discovery,” which would “inform its claim selection.” 10 Opp’n at 7, 9. Defendant seeks to limit the asserted claims to a total of 32, Mot. at 10, 11 while Plaintiff requests the Court ignore Defendant’s proposal entirely, or alternatively, to 12 allow it to proceed on 60 asserted claims to be decided within fourteen days of receiving 13 Defendant’s invalidity contentions, Opp’n at 16. 14 Importantly, the Parties’ moving papers were premised upon Defendant having not 15 yet complied with the at-the-time forthcoming September 10, 2024 deadline for serving 16 invalidity contentions pursuant to Patent L.R. 3.3. See ECF No. 67 (“Case Management 17 Order”) at 2. Defendant identifies “the extraordinary, wasteful effort that would be 18 required to prepare detailed invalidity contentions as to the 130 currently asserted claims.” 19 Mot. at 3. Meanwhile, Plaintiff avers that it “should receive the benefit of those 20 contentions before voluntarily reducing its case.” Opp’n at 11. At the present time, 21 however, the invalidity contentions deadline has come and gone, and to the Court’s 22 knowledge, Defendant properly served its contentions in compliance with the Case 23 Management Order.2 24 25 26 1 Pin citations refer to the CM/ECF numbers electronically stamped at the top of each page.

27 2 Indeed, on September 19, 2024, Defendant filed a letter with the Court stating it “served a set of amended 28 invalidity contentions, in compliance with the current schedule, as to all 130 claims.” ECF No. 96 at 2. 1 LEGAL STANDARD 2 District courts may limit the number of patent claims asserted in an action for patent 3 infringement for the sake of judicial economy and management of a court’s docket. See In 4 re Katz Interactive Call Processing Patent Litig., 639 F.3d 1303, 1313 (Fed. Cir. 2011); 5 Stamps.com Inc. v. Endicia, Inc., 437 F. App’x 897, 902 (Fed. Cir. 2011); Medtronic 6 Minimed Inc. v. Animas Corp., No. CV 12-04471 RSWL RZX, 2013 WL 3322248, at *1 7 (C.D. Cal. Apr. 5, 2013) (collecting cases). “In determining whether to require parties [to] 8 limit the number of claims asserted, courts look to” several factors, including “the number 9 of patents and claims at issue[,] the feasibility of trying the claims to a jury[,] . . . whether 10 the patents at issue have common genealogy, whether the patents contain terminal 11 disclaimers, and whether the asserted claims are duplicative.” Thought, Inc. v. Oracle 12 Corp., No. 12-CV-05601-WHO, 2013 WL 5587559, at *2 (N.D. Cal. Oct. 10, 2013) (citing 13 In re Katz, 639 F.3d at 1311). “Even after requiring parties to limit the number of claims 14 at issue for claim construction or trial, courts should allow patent holders to bring back in 15 non[-]selected claims upon a showing of ‘good cause’ that the non-selected claims present 16 unique issues of infringement or invalidity.” Id. (citing Masimo Corp. v. Philips Elecs. N. 17 Am. Corp., 918 F. Supp. 2d 277, 284 (D. Del. 2013)). 18 ANALYSIS 19 Defendant argues that allowing Plaintiff to proceed into the discovery and claim 20 construction phases on all of its asserted claims would result in “undue prejudice” to 21 Defendant and a “waste of party and judicial resources.” Mot. at 2. Many, if not most, of 22 the asserted claims will never be tried, Defendant says, so it would be wasteful for the 23 Parties to exchange contentions and engage in claim construction on all of the asserted 24 claims. Id. at 6. Defendant goes on to argue that any prejudice that might result to Plaintiff 25 by the narrowing of its claims at this juncture is further minimized by “the duplicative 26 27 28 as Plaintiff filed a responsive letter with the Court the next day that does not dispute the statement. See 1 nature of the patents and claims.” Id. 2 Plaintiff offers no intimation of bringing all 128 claims to trial but counters that the 3 Court should afford it “the benefit of fact and contentions discovery before forcing large 4 reductions.” Opp’n at 3. Plaintiff points to receipt of invalidity contentions as a critical 5 milestone through which it should be able to maintain the asserted claims, id. at 11, 6 particularly in light of “key distinctions among the asserted patents,” id. at 12. 7 Plaintiff raises three stages of this litigation as critical junctures after which it would 8 have received the information necessary to properly inform its claim selections: 9 “meaningful fact discovery,” receipt of invalidity contentions, and claim construction. Id. 10 at 7. As to the fact discovery that it seeks, Plaintiff specifically cites: samples of the 11 accused products; documentation comparing various spinal implants; identification of 12 persons with knowledge relevant to the accused products; documentation relating to 13 research and development, manufacturing, distribution, and sale of the accused products; 14 documentation relating to advertising or marketing of the accused products; and 15 documentation relating to objective indicia of non-obviousness. Id. at 10. 16 The Court is not persuaded that Plaintiff needs more time to narrow its claims. 17 Plaintiff asserts that “courts have afforded plaintiffs the benefit of the court’s claim 18 constructions before forcing claim selections,” but the cases Plaintiff relies on betray that 19 conclusion. See, e.g., Arctic Cat, Inc. v. Polaris Indus Inc., No. 13-3579 (JRT/FLN), 20 2015 WL 3756409, at *4 (D. Minn. June 12, 2015) (“It is equally clear to this Court, 21 however, that waiting to reduce claims until after claim construction would be too late in 22 the litigation process. Indeed, the vast majority of courts that have ordered claim reduction 23 have done so prior to claim construction.” (citing Masimo, 918 F. Supp. 2d at 282–84; 24 Thought, Inc. v. Oracle Corp., No. 12-cv-5601, 2013 WL 5587559 (N.D. Cal. Oct. 10, 25 2013); Round Rock Rsch, LLC v. Dell Inc., No. 4:11-cv-332, 2012 WL 8017390 (E.D. Tex. 26 Mar. 26, 2012))).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stamps.com Inc. v. Endicia, Inc.
437 F. App'x 897 (Federal Circuit, 2011)
United States v. Benn
437 F. App'x 21 (Second Circuit, 2011)
Katz v. American Airlines, Inc.
639 F.3d 1303 (Federal Circuit, 2011)
Masimo Corp. v. Philips Electronics North America Corp.
918 F. Supp. 2d 277 (D. Delaware, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
4WEB, Inc. v. NuVasive, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/4web-inc-v-nuvasive-inc-casd-2024.